ZYUS Life Sciences Advances Phase 2A Trial for Non-Opioid Cancer Pain Drug

Tip Ranks
2025.05.22 11:46
portai
I'm PortAI, I can summarize articles.

ZYUS Life Sciences (TSE:ZYUS) is advancing its Phase 2A clinical trial, UTOPIA-1, to evaluate the safety and efficacy of Trichomylin softgel capsules for cancer-related pain management. This trial aims to provide alternative treatments to opioids, highlighting the potential of cannabinoids in oncology. Analysts rate ZYUS stock as a Buy with a price target of C$1.50. The company focuses on developing cannabinoid-based pharmaceuticals and securing regulatory approvals for non-opioid solutions.

Confident Investing Starts Here:

  • Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
  • Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

ZYUS Life Sciences ( (TSE:ZYUS) ) has shared an update.

ZYUS Life Sciences is finalizing site initiation for its Phase 2A clinical trial, UTOPIA-1, which aims to test the safety and efficacy of Trichomylin softgel capsules for managing cancer-related pain. This trial marks a significant step in providing alternative, evidence-based treatments to conventional pain management therapies like opioids, aligning with the growing recognition of cannabinoids’ potential in oncology.

The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.

More about ZYUS Life Sciences

ZYUS Life Sciences Corporation is a Canadian-based life sciences company specializing in the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. The company is committed to advancing evidence-based therapies, securing intellectual property protection, and obtaining regulatory approval for non-opioid-based pharmaceutical solutions.

Average Trading Volume: 16,928

Technical Sentiment Signal: Sell

Current Market Cap: C$35.28M

For a thorough assessment of ZYUS stock, go to TipRanks’ Stock Analysis page.

Trending Articles:

  • ‘Stay on Board,’ Says Top Investor About Nvidia Stock
  • ‘Buy After Google I/O,’ Says Morgan Stanley About Alphabet Stock
  • Wolfspeed Stock Collapses: Here’s What J.P. Morgan Says About the Road to Bankruptcy

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.